These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 32692113)

  • 1. Neurocognitive Effects of Antiretroviral Initiation Among People Living With HIV in Rural Uganda.
    Vecchio A; Robertson K; Saylor D; Nakigozi G; Nakasujja N; Kisakye A; Batte J; Mayanja R; Anok A; Reynolds SJ; Quinn TC; Gray R; Wawer MJ; Sacktor N; Rubin LH
    J Acquir Immune Defic Syndr; 2020 Aug; 84(5):534-542. PubMed ID: 32692113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity in neurocognitive change trajectories among people with HIV starting antiretroviral therapy in Rakai, Uganda.
    Rubin LH; Saylor D; Nakigozi G; Nakasujja N; Robertson K; Kisakye A; Batte J; Mayanja R; Anok A; Lofgren SM; Boulware DR; Dastgheyb R; Reynolds SJ; Quinn TC; Gray RH; Wawer MJ; Sacktor N
    J Neurovirol; 2019 Dec; 25(6):800-813. PubMed ID: 31218522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV.
    Huang SH; Huang WC; Lin SW; Chuang YC; Sun HY; Chang SY; Kuo PH; Wu PY; Liu WC; Chiang C; Hung CC; Chang SC
    J Acquir Immune Defic Syndr; 2021 Jun; 87(2):834-841. PubMed ID: 33587507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
    Chang JL; Lee SA; Tsai AC; Musinguzi N; Muzoora C; Bwana B; Boum Y; Haberer JE; Hunt PW; Martin J; Bangsberg DR; Kroetz DL; Siedner MJ
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):982-992. PubMed ID: 29973058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of HIV Subtype and Antiretroviral Therapy on HIV-Associated Neurocognitive Disorder Stage in Rakai, Uganda.
    Sacktor N; Saylor D; Nakigozi G; Nakasujja N; Robertson K; Grabowski MK; Kisakye A; Batte J; Mayanja R; Anok A; Gray RH; Wawer MJ
    J Acquir Immune Defic Syndr; 2019 Jun; 81(2):216-223. PubMed ID: 30865184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efavirenz use and neurocognitive performance among older people living with HIV who were on antiretroviral therapy.
    Qin P; He J; Wang Z; Chen X; Li J; Fung AWT; Jiang H; Chen J; Wong A; Lau JTF
    AIDS Care; 2020 Jan; 32(1):12-20. PubMed ID: 31142146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study.
    Chang JL; Tsai AC; Musinguzi N; Haberer JE; Boum Y; Muzoora C; Bwana M; Martin JN; Hunt PW; Bangsberg DR; Siedner MJ
    Ann Intern Med; 2018 Aug; 169(3):146-155. PubMed ID: 29946683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal neuropsychological test performance among HIV seropositive individuals in Uganda.
    Sacktor N; Nakasujja N; Okonkwo O; Skolasky RL; Robertson K; Musisi S; Katabira E
    J Neurovirol; 2013 Feb; 19(1):48-56. PubMed ID: 23315423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of age on CD4 recovery and viral suppression over time among adults living with HIV who initiated antiretroviral therapy in the African Cohort Study.
    Bahemana E; Esber A; Dear N; Ganesan K; Parikh A; Reed D; Maganga L; Khamadi S; Mizinduko M; Lwilla A; Mkondoo D; Mwaisanga G; Somi N; Owouth J; Maswai J; Kiweewa F; Iroezindu M; Ake JA; Crowell TA; Valcour VG; Polyak CS;
    AIDS Res Ther; 2020 Nov; 17(1):66. PubMed ID: 33183355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
    Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
    J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study.
    Mellgren Å; Eriksson LE; Reinius M; Marrone G; Svedhem V
    PLoS One; 2020; 15(12):e0242710. PubMed ID: 33362248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances.
    Lapadula G; Bernasconi DP; Bai F; Focà E; Di Biagio A; Bonora S; Castelli F; Squillace N; Bandera A; Monforte AD; Migliorino GM; Gori A;
    AIDS; 2020 Jan; 34(1):53-61. PubMed ID: 31567160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy outcomes following exposure to efavirenz based antiretroviral therapy in indian women.
    Mishra RK; Chakravarty R; Siddique N; Pandey KR
    Indian J Pharmacol; 2020; 52(6):467-471. PubMed ID: 33666186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attention/Working Memory, Learning and Memory in Adult Cameroonians: Normative Data, Effects of HIV Infection and Viral Genotype.
    Kanmogne GD; Fonsah JY; Umlauf A; Moul J; Doh RF; Kengne AM; Tang B; Tagny CT; Nchindap E; Kenmogne L; Franklin D; Njamnshi DM; Mbanya D; Njamnshi AK; Heaton RK
    J Int Neuropsychol Soc; 2020 Jul; 26(6):607-623. PubMed ID: 32066518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depressive Symptoms Before and After Antiretroviral Therapy Initiation Among Older-Aged Individuals in Rural Uganda.
    Manne-Goehler J; Kakuhikire B; Abaasabyoona S; Bärnighausen TW; Okello S; Tsai AC; Siedner MJ
    AIDS Behav; 2019 Mar; 23(3):564-571. PubMed ID: 30229388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High efavirenz levels but not neurofilament light plasma levels are associated with poor neurocognitive functioning in asymptomatic HIV patients.
    Hakkers CS; Hermans AM; van Maarseveen EM; Teunissen CE; Verberk IMW; Arends JE; Hoepelman AIM
    J Neurovirol; 2020 Aug; 26(4):572-580. PubMed ID: 32524424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depression is associated with efavirenz-containing treatments in newly antiretroviral therapy initiated HIV patients in Ecuador.
    Checa A; Castillo A; Camacho M; Tapia W; Hernandez I; Teran E
    AIDS Res Ther; 2020 Jul; 17(1):47. PubMed ID: 32727488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex-specific associations between cerebrospinal fluid inflammatory marker levels and cognitive function in antiretroviral treated people living with HIV in rural Uganda.
    Vecchio AC; Williams DW; Xu Y; Yu D; Saylor D; Lofgren S; O'Toole R; Boulware DR; Nakasujja N; Nakigozi G; Kisakye A; Batte J; Mayanja R; Anok A; Reynolds SJ; Quinn TC; Gray RH; Wawer MJ; Sacktor N; Rubin LH
    Brain Behav Immun; 2021 Mar; 93():111-118. PubMed ID: 33359628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurocognitive impairment in treatment-experienced adults living with HIV attending primary care clinics in Zimbabwe.
    Nyamayaro P; Gouse H; Hakim J; Robbins RN; Chibanda D
    BMC Infect Dis; 2020 May; 20(1):383. PubMed ID: 32471350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.
    Nichols SL; Bethel J; Kapogiannis BG; Li T; Woods SP; Patton ED; Ren W; Thornton SE; Major-Wilson HO; Puga AM; Sleasman JW; Rudy BJ; Wilson CM; Garvie PA;
    J Neurovirol; 2016 Apr; 22(2):218-30. PubMed ID: 26463526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.